166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel

Nuclear Medicine and Biology

Volumn 41, Issue 3, 2014, Pages 276-281

  Thompson, S ^a   Ballard, B ^a   Jiang, Z ^b   Revskaya, E ^b   Sisay, N ^c   Miller, W H ^c   Cutler, C S ^c   Dadachova, E ^b   Francesconi, L C ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

Antibody; Melanoma; Radioisotopes; Radiotherapy

Indexed keywords

ANTIBODY; DIAGNOSTIC AGENT; HOLMIUM; MONOCLONAL ANTIBODY; PENTETIC ACID; RADIOISOTOPE; YTTRIUM;

ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DRUG STABILITY; EXPERIMENTAL MELANOMA; FEMALE; HALF LIFE TIME; HUMAN; IMMUNOLOGY; MELANOMA; METHODOLOGY; MOUSE; NUDE MOUSE; PATHOLOGY; RADIOIMMUNOTHERAPY; RADIOTHERAPY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANTIBODY; MELANOMA; RADIOISOTOPES; RADIOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DRUG STABILITY; FEMALE; HALF-LIFE; HOLMIUM; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; PENTETIC ACID; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 84893970954     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.12.015     Document Type: Article

References (27)

1. Linos E., Swetter S.M., Cockburn M.G., Colditz G.A., Clarke C.A. Increasing burden of melanoma in the United States. J Investig Dermatol 2009, 129:1666-1674.
2. Hodi F.S., O'Day S.J., McDermott D.F. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
3. Chapman P.B., Hauschild A., Robert C. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. J Clin Oncol 2011, 29. [Suppl; abstr LBA4].
4. Ribas A., Kim A.B., Schuchter L.M. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011, 29. abstr 8509.
5. Dadachova E., Nosanchuk J.D., Shi L., Schweitzer A.D., Frenkel A., Nosanchuk J.S. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A 2004, 101:14865-14870.
6. Dadachova E., Revskaya E., Sesay M.A., Damania H., Boucher R., Sellers R.S. Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther 2008, 7:1116-1127.
7. Klein M., Lotem T., Peretz S.T., Zwas S., Mizrachi Y., Liberman R., et al. Safety and efficacy of 188-Rhenium-labeled antibody to melanin in patients with metastatic melanoma. J. Skin Cancer 2013, 828329.
8. Miao Y., Quinn T.P. Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol 2008, 67:213-228.
9. 177Lu. Bioconjug Chem 2006, 17:485-492.
10. Lewis M., Zhang J., Jia F., Owen N.K., Cutler C.S. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol 2004, 31:213-223.
11. Capello A., Krenning E., Breeman W.A., Bernard B.F., Konijnenbert M.W., deJong M. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm 2003, 18:761-768.
12. Mohsin H., Jia F., Bryan J.N., Sivaguru G., Cutler C.S., Ketring A.R. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu. Bioconjug Chem 2011, 22:2444-2452.
13. Hu F., Cutler C.S., Hoffman T., Sieckman G., Volkert W.A., Jurisson S.S. Pm-149 DOTA bombesin analogs for potential radiotherapy in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-bAla-BBN(7-14)NH2. Nucl Med Biol 2002, 29:423-430.
14. Noble J.E., Bailey M.J.A. Quantitation of protein. Guide to protein purification 2009, 463:73-95. Elsevier Academic Press Inc., San Diego. Second ed. R.R. Burgess, M.P. Deutscher (Eds.).
15. Pippen C.G., Parker T.A., McMurry T.J., Brechiel M.W. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem 1992, 3:342-344.
16. Karacay H., Sharkey R.M., Gold D.V., Ragland D.R., McBride W.J., Rossi E.A. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med 2009, 50:2008-2016.
17. Mattes M.J., Sharkey R.M., Karacay H., Czuczman M.S., Goldenberg D.M. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res 2008, 14:6154-6160.
18. 64Cu radioisotopes. Cancer Biother Radiopharm 2005, 18:436-449.
19. Hui T.E., Fisher D.R., Kuhn J.A. A mouse model for calculating cross-organ β doses from yttrium-90-labeled immunoconjugates. Cancer 1994, 73(supplement):951-957.
20. 99mTc labeled Anti-NCA-95 MAbs. J Nucl Med 2000, 41:531-537.
21. McMurry T.J., Pippin C.G., Wu C.C., Deal K.A., Brechbiel M.W., Mirzadeh S. Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates. J Med Chem 1998, 41:3546-3549.
22. Roselli M., Milenic D.E., Brechbiel M.W., Mirzadeh S., Pippin C.G., Gansow O.A. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts. Cancer Biother Radiopharm 1999, 14:209-220.
23. Heldt J.M., Koi L., Zenker M., Bruchner K., Dittfeld C., Bergmann R. Development of Y-90 Y-CHX-A ''-DTPA-cetuximab for combination of radioimmunotherapy and external radiotherapy: radiochemistry and first in vivo results. J Label Compd Radiopharm 2011, 54:S568-S568.
24. Adams G.P., Shaller C.C., Dadachova E., Simmons H.H., Horak E.M., Tesfaye A. A single treatment of yttrium-90-labeled CHX-A''-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 2004, 64:6200-6206.
25. O'Mahony D., Janik J.E., Carrasquillo J.A., Brechbiel M., Paik C.H., Le N. Yttrium-90 radiolabeled humanized anti-CD25 monoclonal antibody, daclizumab, provides effective therapy for refractory and relapsed Hodgkin's lymphoma. Haematol Hematol J 2007, 92:18-19.
26. Vallera D.A., Sicheneder A.R., Taras E.P., Brechbiel M.W., Vallera J.A., Panoskaltsis-Mortari A. Radiotherapy of CD45-expressing daudi tumors in nude mice with yttrium-90-labeled, PEGylated Anti-CD45 antibody. Cancer Biother Radiopharm 2007 Aug, 22(4):488-500.
27. D'Huyvetter M., Aerts A., Xavier C., Vaneycken I., Devoogdt N., Gijs M. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging 2012, 7:254-264.